| Literature DB >> 24341511 |
Noah M Ivers1, Karen Tu, Jacqueline Young, Jill J Francis, Jan Barnsley, Baiju R Shah, Ross E Upshur, Rahim Moineddin, Jeremy M Grimshaw, Merrick Zwarenstein.
Abstract
BACKGROUND: Audit and feedback to physicians is a commonly used quality improvement strategy, but its optimal design is unknown. This trial tested the effects of a theory-informed worksheet to facilitate goal setting and action planning, appended to feedback reports on chronic disease management, compared to feedback reports provided without these worksheets.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24341511 PMCID: PMC3878579 DOI: 10.1186/1748-5908-8-142
Source DB: PubMed Journal: Implement Sci ISSN: 1748-5908 Impact factor: 7.327
Intervention components and description
| Feedback reports | One page focusing on patients with diabetes and one on patients with heart disease. Aggregate rather than patient-specific data provided. Performance compared to top 10% of peers, presented in tables and bar graphs. |
| Explanatory document | One page description of how data was generated, including possible limitations. |
| Suggestions document | One page with clinical recommendations (ie. managing muscle aches for patients taking statins) and generic quality improvement strategies ( |
| Continuing medical education form | Two-page self-reflection survey required by the College of Family Physicians to earn continuing medical education credits related to practice audits. |
Composite process score calculated for each patient as primary process outcome
| BP test in 6 M | X | X | X |
| A1C test in 6 M | X | | X |
| FBG test in 24 M | | X | |
| LDL test in 12 M | X | X | X |
| ACR test in 12 M | X | | X |
| Rx ASA | | X | X |
| Rx Statin | X | X | X |
| Rx ACE/ARB | X | X | X |
IHD ischemic heart disease, BP blood pressure, A1C haemoglobin A1c, FBG fasting blood glucose, LDL low density lipoprotein cholesterol, ACR urinary albumin-to-creatinine ratio, ASA aspirin, ACE/ARB angiotensin-modifying agent.
Figure 1Cluster-Patient flow diagram.
Baseline characteristics of clinics, and family physicians
| 7 | 7 | |
| Total patients (median, IQR) | 3,121 (2,258 – 2,671) | 4,432 (3,488 – 8,201) |
| Eligible* patients (median, IQR) | 205 (189 – 389) | 257 (211 – 499) |
| Location (n, % rural) | 4 (57%) | 2 (29%) |
| 22 | 31 | |
| Roster size (median, IQR) | 1,010 (596 – 1,416) | 1,291 (884 – 1,696) |
| Sex (n, % female) | 6 (27%) | 19 (61%) |
| Years in practice (median, IQR) | 23 (16 – 25) | 15 (7 – 22) |
| Years using EMR (median, IQR) | 7 (6.7 – 7.9) | 6 (6.2 – 6.6) |
| Eligible* patients (median, IQR) | 77 (49 – 120) | 179 (62 – 216) |
*Eligible patients are those meeting inclusion criteria with diabetes and/or heart disease.
IQR = interquartile range, % = proportion.
Baseline characteristics of patients
| 2,157 | 2,460 | - | |
| IHD only | 545 (25%) | 637 (26%) | - |
| DM only | 1,329 (62%) | 1,534 (62%) | - |
| IHD and DM | 283 (13%) | 289 (12%) | - |
| Age (mean years ± sd) | 67 ±14 | 65 ±14 | - |
| Female | 906 (42%) | 1,251 (46%) | - |
| WT (mean kg ± sd) | 88 ±22 | 90 ±29 | 0.047 |
| Systolic BP (mean mmHg ± sd) | 130 ±18 | 129 ±17 | 0.058 |
| Diastolic BP (mean mmHg ± sd) | 73 ±11 | 75 ±11 | 0.079 |
| LDL (mean mmol/l ± sd) | 2.3 ±0.9 | 2.3 ±0.9 | 0.053 |
| HbA1c^ (mean% ± sd) | 7.4 ±1.4 | 7.3 ±1.4 | 0.011 |
| LDL at target~ | 665 (31%) | 826 (34%) | 0.051 |
| BP at target~ | 1,019 (47%) | 1,054 (43%) | 0.071 |
| BP test in 6 M | 1,839 (85%) | 1,831 (74%) | 0.183 |
| A1C test in 6 M^ | 1,267 (79%) | 1,250 (69%) | 0.079 |
| FBG test in 24 M | 1,904 (88%) | 2,134 (87%) | 0.091 |
| LDL test in 12 M | 1,574 (73%) | 1,770 (72%) | 0.096 |
| ACR test in 12 M^ | 1,044 (65%) | 1,232 (68%) | 0.195 |
| Rx ASA* | 602 (73%) | 657 (71%) | 0.092 |
| Rx Statin | 1,463 (68%) | 1,757 (71%) | 0.051 |
| Rx ACE/ARB^ | 1,153 (71%) | 1,243 (68%) | 0.068 |
| Rx Beta blocker* | 497 (60%) | 562 (61%) | 0.008 |
| Rx insulin^ | 339 (21%) | 391 (21%) | 0.006 |
| Composite process score (mean ± sd) | 73 ±25 | 71 ±27 | 0.106 |
Legend: ICC = Intra-cluster correlation reported at physician-level, ^ = Calculated for patients with diabetes, * Calculated for patients with IHD, ~ = Target BP 130/80 for diabetes but 140/90 for IHD and Target LDL < 2, IHD = ischemic heart disease, BP = blood pressure, A1C = haemoglobin A1c, FBG = fasting blood glucose, LDL = low density lipoprotein cholesterol, ACR = urinary albumin-to-creatinine ratio, ASA = aspirin, ACE/ARB = angiotensin-modifying agent, kg = kilogram, sd = standard deviation.
Outcomes for patients receiving feedback plus the goal-setting and action-planning worksheet versus feedback alone
| | ||||||||
|---|---|---|---|---|---|---|---|---|
| | | |||||||
| Systolic BP | 128 ±18 | 128 ±16 | 0.35 | -2.24, 2.95 | -0.05 | -2.11, 2.02 | ||
| Diastolic BP | 72 ±11 | 73 ±11 | -1.48 | -3.34, 0.38 | -0.72 | -2.18, 0.75 | ||
| LDL | 2.1 ±0.8 | 2.0 ±0.8 | 0.04 | -0.06, 0.14 | 0.04 | -0.02, 0.10 | ||
| HbA1c%^ | 7.2 ±1.3 | 7.4 ±1.5 | -0.24 | -0.38, -0.09 | -0.20 | -0.33, -0.06 | ||
| Composite score | 72 ±26 | 70 ±28 | 4.85 | -0.52, 10.21 | 1.76 | -1.37, 4.89 | ||
| | | | | |||||
| LDL at target | 866 (47%) | 1,119 (50%) | 0.97 | 0.85, 1.13 | | 0.97 | 0.90, 1.06 | |
| BP at target | 965 (53%) | 1,023 (46%) | 1.21 | 1.05, 1.40 | | 1.15 | 1.02, 1.29 | |
| BP test in 6 M | 1,491 (81%) | 1,541 (69%) | 1.25 | 1.11, 1.42 | | 1.16 | 1.06, 1.26 | |
| A1C test in 6 M^ | 947 (71%) | 1,067 (65%) | 1.12 | 0.98, 1.28 | | 1.07 | 0.95, 1.21 | |
| FBG test in 24 M | 1,596 (87%) | 1,918 (86%) | 1.03 | 0.97, 1.10 | | 1.03 | 0.98, 1.08 | |
| LDL test in 12 M | 1,217 (66%) | 1,480 (67%) | 1.03 | 0.93, 1.16 | | 1.02 | 0.93, 1.12 | |
| ACR test in 12 M^ | 851 (64%) | 1,060 (65%) | 1.02 | 0.87, 1.20 | | 1.05 | 0.93, 1.20 | |
| Rx ASA* | 552 (75%) | 615 (73%) | 1.03 | 0.95, 1.11 | | 0.99 | 0.96, 1.03 | |
| Rx statin | 1,309 (72%) | 1,686 (76%) | 0.96 | 0.89, 1.03 | | 0.97 | 0.94, 1.00 | |
| Rx ACE/ARB^ | 647 (83%) | 679 (84%) | 1.05 | 0.97, 1.14 | | 0.98 | 0.95, 1.00 | |
| Rx beta blocker* | 440 (59%) | 514 (61%) | 1.00 | 0.90, 1.10 | | 0.99 | 0.95, 1.03 | |
| Rx insulin^ | 351 (26%) | 426 (26%) | 0.99 | 0.85, 1.16 | 1.01 | 0.99, 1.04 | ||
All models adjusted for clustering. Adjusted models also controlled for baseline values of dependent variable.
Legend: ^Analysis restricted to patients with diabetes, *Analysis restricted to patients with IHD, ~ Target BP 130/80 for diabetes and 140/90 for IHD and Target LDL<2.
MD mean difference, RR relative risk, IHD ischemic heart disease, BP blood pressure, A1C haemoglobin A1c, FBG fasting blood glucose, LDL low density lipoprotein cholesterol, ACR albumin-to-creatinine ratio, ASA aspirin, ACE/ARB angiotensin-modifying agent, Rx active prescription, CI confidence interval, M months.